Nefertiti C Dupont, MD | |
1836 South Ave, La Crosse, WI 54601-5429 | |
(608) 782-7300 | |
Not Available |
Full Name | Nefertiti C Dupont |
---|---|
Gender | Female |
Speciality | Gynecological Oncology |
Experience | 25 Years |
Location | 1836 South Ave, La Crosse, Wisconsin |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326105511 | NPI | - | NPPES |
03023094 | Medicaid | NY | |
337897801 | Medicaid | TX | |
337897802 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | Q1136 (Texas) | Secondary |
207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | 71572 (Wisconsin) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
Houston Methodist The Woodlands Hospital | The woodlands, TX | Hospital |
Memorial Hermann Hospital System | Houston, TX | Hospital |
Entity Name | Texienne Oncology Centers, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1700017449 PECOS PAC ID: 7012054281 Enrollment ID: O20091020000492 |
News Archive
Public health professionals from across the country will convene July 14-15 in Indianapolis for a national summit on ethical and policy issues faced by public health officials and the medical community while preparing for a large-scale epidemic.
To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.
A common genetic variant that affects 1 in 3 people significantly increases the risk of colorectal cancer from the consumption of red meat and processed meat, according to a study presented today at the annual American Society of Human Genetics 2013 meeting, the largest gathering of human geneticists in the world.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 1 days ago
Entity Name | North Houston Gynecologic Oncology Surgeons Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1669927752 PECOS PAC ID: 4789965062 Enrollment ID: O20161228000687 |
News Archive
Public health professionals from across the country will convene July 14-15 in Indianapolis for a national summit on ethical and policy issues faced by public health officials and the medical community while preparing for a large-scale epidemic.
To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.
A common genetic variant that affects 1 in 3 people significantly increases the risk of colorectal cancer from the consumption of red meat and processed meat, according to a study presented today at the annual American Society of Human Genetics 2013 meeting, the largest gathering of human geneticists in the world.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 1 days ago
Entity Name | East Texas Clinical Services Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1326596776 PECOS PAC ID: 8224319983 Enrollment ID: O20170111002911 |
News Archive
Public health professionals from across the country will convene July 14-15 in Indianapolis for a national summit on ethical and policy issues faced by public health officials and the medical community while preparing for a large-scale epidemic.
To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.
A common genetic variant that affects 1 in 3 people significantly increases the risk of colorectal cancer from the consumption of red meat and processed meat, according to a study presented today at the annual American Society of Human Genetics 2013 meeting, the largest gathering of human geneticists in the world.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Nefertiti C Dupont, MD 9201 Pinecroft Dr, Shenandoah, TX 77380-3222 Ph: (936) 447-9490 | Nefertiti C Dupont, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
Public health professionals from across the country will convene July 14-15 in Indianapolis for a national summit on ethical and policy issues faced by public health officials and the medical community while preparing for a large-scale epidemic.
To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.
A common genetic variant that affects 1 in 3 people significantly increases the risk of colorectal cancer from the consumption of red meat and processed meat, according to a study presented today at the annual American Society of Human Genetics 2013 meeting, the largest gathering of human geneticists in the world.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 1 days ago
Theodore M Peck, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Dayna Patricia Schwarz, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-392-9866 Fax: 608-392-3888 | |
Dr. Lauren Allen Scott, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Catherine R Ryan, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Dana M Benden, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Harry Franklin Farb, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Kenneth W Merkitch, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |